Ecotoxicology of Human Pharmaceuticals: Unraveling the Impact on Aquatic Ecosystems

Karl Weston^*
*Correspondence: Karl Weston, Department of Environmental Technology, University of Applied Sciences Basel, Muttenz, Switzerland, Email:

Keywords

Pharmaceuticals • Ecotoxicological effects • Environmental toxicity

Introduction

The widespread use of pharmaceuticals to treat a myriad of human ailments has led to an inadvertent side effect: the introduction of these compounds into aquatic environments. Through a complex pathway that involves human excretion, wastewater treatment processes, and eventual discharge into rivers, lakes, and oceans, pharmaceuticals find their way into the very ecosystems that sustain life [1].

Minimal quantities of human pharmaceuticals have been identified in Sewage Treatment Plant (STP) discharges, surface waters, seawaters, groundwater, and select drinking water sources across various countries. While certain pharmaceuticals have undergone acute toxicity assessments to gauge their impact on aquatic organisms, their chronic toxicity potential and subtle repercussions remain largely unexplored. This article critically examines the present comprehension of human pharmaceuticals within the environmental context, tackling several fundamental queries. What types of pharmaceuticals are present in aquatic surroundings, and at what concentrations? How do these compounds behave in surface waters and STPs? Do these substances employ similar mechanisms of action in humans and lower animals? What immediate and prolonged ecotoxicological consequences might emerge from pharmaceutical exposure, both individually and as mixtures? How do these effect concentrations correspond to environmental levels? Our analysis underscores the limited understanding of the extended ramifications of pharmaceutical exposure on aquatic organisms, particularly concerning biological targets. Generally, acute impacts on aquatic organisms due to most studied pharmaceuticals are improbable, barring unforeseen spills [2,3].

Description

The ecotoxicological puzzle unveiled

Ecotoxicology, a branch of environmental science, seeks to comprehend the impact of contaminants on organisms, populations, and ecosystems. When it comes to pharmaceuticals, the puzzle is intricate. While these compounds are designed to target specific biological pathways in humans, their effects on non-target organisms in aquatic environments can be profound.

Chronic Lowest Observed Effect Concentrations (LOEC) for established pharmaceuticals in standard lab organisms surpass STP effluent concentrations by approximately two orders of magnitude. In specific cases, such as diclofenac, the LOEC for fish toxicity was within the range of wastewater concentrations, while propranolol and fluoxetine exhibited LOECs for zooplankton and benthic organisms that closely approached maximal measured STP effluent concentrations. In surface water bodies, concentrations are lower, consequently reducing environmental risks. However, comprehensive ecotoxicological investigations targeting subtle environmental impacts remain largely deficient, necessitating focused research. Such endeavors will facilitate more comprehensive and accurate risk assessments of pharmaceuticals in the evolving landscape [4].

Pharmaceuticals' effect on aquatic life: A multifaceted challenge

Bioaccumulation: Pharmaceuticals can accumulate in organisms over time, leading to elevated concentrations as they move up the food chain. This bioaccumulation can have cascading effects on predator-prey dynamics and ecosystem health.

Endocrine disruption: Many pharmaceuticals, such as hormonal medications, can disrupt the endocrine systems of aquatic organisms, affecting reproduction, development, and behavior. Fish, for instance, can exhibit altered reproductive patterns due to exposure to estrogen-mimicking compounds.

Antibiotic resistance: The widespread use of antibiotics has led to the development of antibiotic-resistant bacteria. These resistant strains can be disseminated to aquatic environments through wastewater discharge, potentially exacerbating the global challenge of antibiotic resistance.

Behavioral changes: Pharmaceuticals can influence the behavior of aquatic organisms, altering feeding patterns, predator avoidance, and even migration, which can have cascading effects on ecosystem dynamics.

Population dynamics: The sublethal effects of pharmaceutical exposure can influence population dynamics, leading to changes in species abundance and diversity within aquatic ecosystems [5].

Navigating toward solutions: A call for action

Pharmaceutical disposal and management: Improved disposal practices for unused medications and enhanced pharmaceutical waste management can curtail the entry of these compounds into aquatic systems.

Advanced wastewater treatment: The development and implementation of advanced wastewater treatment technologies can help remove pharmaceutical compounds from effluents before they reach water bodies.

Eco-friendly drug design: The incorporation of ecotoxicological assessments into the drug development process can aid in designing pharmaceuticals that are less harmful to aquatic life.

Regulation and monitoring: Stringent regulations and regular monitoring of pharmaceutical contamination in water bodies can help mitigate its impact on aquatic ecosystems.

Public awareness and education: Raising awareness among the public, healthcare professionals, and policymakers about the potential ecotoxicological consequences of pharmaceuticals can drive responsible usage and disposal practices [6].

Conclusion

The realm of ecotoxicology provides a sobering reminder of the intricate connections that exist between human activities and the natural world. The ecotoxicological study of human pharmaceuticals underscores the urgent need for a holistic approach that harmonizes human well-being with environmental health. By bridging the gap between scientific research, regulatory action, and public awareness, we can work together to safeguard the delicate balance of aquatic ecosystems for present and future generations.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Andersen, Henrik Rasmus, Leah Wollenberger, Bent Halling‐Sørensen and Kresten Ole Kusk. "Development of copepod nauplii to copepodites-a parameter for chronic toxicity including endocrine disruption." Environ Toxicol Chem: Internat J 20 (2001): 2821-2829.

Google Scholar, Indexed at

2. Andersen, Oivind, Vincent GH Eijsink and Magny Thomassen. "Multiple variants of the Peroxisome Proliferator-Activated Receptor (PPAR) γ are expressed in the liver of Atlantic salmon (Salmo salar)." Gene 255 (2000): 411-418.

Google Scholar, Indexed at

3. Anderson, Paul D., Vincent J D'Aco, Peter Shanahan and Steven C Chapra, et al. "Screening analysis of human pharmaceutical compounds in US surface waters." Environ Sci Tech 38 (2004): 838-849.

Google Scholar, Crossref, Indexed at

4. Andreozzi, Roberto, Marotta Raffaele and Paxéus Nicklas. "Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment." Chemosphere 50 (2003): 1319-1330.

Google Scholar, Crossref, Indexed at

5. Avdeef, A., KJ Box, JEA Comer and C Hibbert, et al. "pH-Metric logP 10. Determination of liposomal membrane-water partition coefficients of lonizable drugs." Pharmaceut Res 15 (1998): 209-215.

Google Scholar, Indexed at

6. Banks, Alpha T., Hyman J Zimmerman, Kamal G Ishak and John G Harter. "Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions." Hepatol 22 (1995): 820-827.

Google Scholar, Crossref, Indexed at